Pazopanib

Drug Profile

Pazopanib

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline; OHSU Knight Cancer Institute
  • Developer GlaxoSmithKline; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; SCRI Development Innovations; University of Minnesota; University of Oxford; University of Washington
  • Class Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Sarcoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Glioma; Hereditary haemorrhagic telangiectasia; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Malignant melanoma
  • Phase I Colorectal cancer; Hepatocellular carcinoma
  • Discontinued Age-related macular degeneration; Inflammatory breast cancer

Most Recent Events

  • 12 Mar 2017 Novartis withdraws a phase II trial prior to enrolment as supporting company withdrew interest in Gastrointestinal stromal tumors (Metastatic disease, Second-line therapy, Combination therapy) (PO) (NCT02342600)
  • 01 Nov 2016 GlaxoSmithKline completes the CATChEz phase II trial for Renal cell carcinoma (First-line therapy, Metastatic disease) in Australia and South Korea (NCT01545817)
  • 28 Oct 2016 GlaxoSmithKline withdraws a phase II trial for Soft tissue sarcoma (Maintenance therapy) prior to enrolment in USA and European Union (NCT02367651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top